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Guidance on the choice of data sources for cost weights
in cost-effectiveness analyses in the literature is scarce
with few empirical examples of cost weights derived from
different approaches.
OBJECTIVES: This paper describes the large differences
that can be found in cost weights derived from different
data sources and analytic approaches. We highlight the
implications of the choice of costing data source and the
magnitude of error that could be introduced by assuming
data parity in direct comparisons of different studies.
Though our examples focus on HIV disease treatment,
the issues we explore are generic to cost estimation for all
conditions.
METHODS: We compared annual HIV disease treatment
cost weights from two data sets, the HIV Cost and 
Services Utilization Study (HCSUS) survey and South
Carolina Medicaid data. Cost weights for hospital and
nursing home stays and emergency room and physician
visits were included in the analyses.
RESULTS: The cost weights for Medicaid patients 
with AIDS were $15,033 in HCSUS and $10,281 in SC
Medicaid data. Within the HCSUS data set, cost weights
also varied greatly depending on whether the patient 
was covered by Medicaid ($15,033), Medicare ($8,487),
private ($4,200), or other public insurance ($19,347).
Further analysis of the HCSUS data found that the 
mean cost estimates for patients were larger when viral
load (VL) data was missing ($8,413) than when it was
included ($5,362). This difference was especially pro-
nounced at higher CD4 cell count ranges. For example,
the mean cost for patients with CD4 200–499 was $3,829
when VL was reported and $6,458 when it was missing,
a difference of 67%.
CONCLUSION: As this research illustrates, there may be
large differences in cost weights that are derived from dif-
ferent data sources and analytic approaches. Accordingly,
they should be given careful consideration when deter-
mining the external validity of economic studies.
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A major weakness of the literature on treatment satisfac-
tion is the lack of rigor in the development of satisfaction
measures. Part of this problem lies in the absence of an
accepted conceptual model for treatment satisfaction.
OBJECTIVES: This paper presents a conceptual mod-
el for treatment satisfaction and uses it to identify the
underlying dimensions associated with smoking cessation
treatments.
METHODS: A systematic literature review of databases
including MEDLINE, ABI-INFORM, Current Contents,
and IPA was conducted. Key words used for the litera-
ture search included drug, patient, smoking, physician,
pharmacist, placebo effect, and treatment satisfaction.
Articles included in the review focused on drug and
provider attributes shown in the literature to be signiﬁ-
cantly associated with overall perceptions of treatment
experiences. Treatment satisfaction attributes involving
high levels of patient-provider contact were emphasized
due to their relevance to smoking cessation treatments.
RESULTS: A conceptual model for treatment satisfaction,
based upon the review, was considered to consist of a
patient’s assessment of salient aspects of the process and
outcome of treatment experiences. Since treatment expe-
riences often contain the administration of both products
and services, the conceptual model was considered to
consist of both product and service attributes. Support
was found in the literature for this conceptualization since
evidence showed that both product and service attributes
have signiﬁcant impact on overall evaluations of treat-
ment experiences. Product-related attributes signiﬁcantly
impacting overall treatment satisfaction were categorized
under four of the product quality dimensions deﬁned by
Garvin (1984): Performance, Features, Aesthetics, and
Perceived Quality. Service-related attributes of treatment
were classiﬁed under the dimensions: Attitude, Respon-
siveness, Communication, Trust, Access, Motivation,
Expertise, and Tangibles.
CONCLUSION: The literature demonstrated support for
a conceptual model of treatment satisfaction with both
product- and service-related attributes. The inclusion of
service attributes is particularly important for treatments
consisting of high levels of patient-provider contact such
as with smoking cessation treatments. The dimensions in
this conceptual model can assist in the development of
treatment satisfaction measures.
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The Institute of Medicine Report on Patient Safety
requests a 50% reduction of adverse events. This
however, poses a challenge from a measurement perspec-
tive. Incidence estimates of adverse events have tradi-
tionally been based on medical case review, which is
exhaustive and costly. Furthermore, the reliability of this
method has been challenged. Recent studies have applied
information technology to screen for adverse drug events
(ADEs) in order to replace chart review.
OBJECTIVE: To explore the extent to which automated
health care data screens can be used to measure the inci-
dence of in-hospital ADEs.
METHODS: Systematic literature review. Keyword
search of MEDLINE (1980–2001) electronic database
and hand search. Included studies had to describe speciﬁc
screens that were applied to clinical or administrative
databases to detect in-hospital ADEs. They also had to
